Byung-Chul Kim and Heung Tae Kim have contributed equally.
Fibroblasts from chronic wounds show altered TGF-β-signaling and decreased TGF-β Type II Receptor expression†
Article first published online: 31 MAR 2003
Copyright © 2003 Wiley-Liss, Inc.
Journal of Cellular Physiology
Volume 195, Issue 3, pages 331–336, June 2003
How to Cite
Kim, B.-C., Kim, H. T., Park, S. H., Cha, J.-S., Yufit, T., Kim, S.-J. and Falanga, V. (2003), Fibroblasts from chronic wounds show altered TGF-β-signaling and decreased TGF-β Type II Receptor expression. J. Cell. Physiol., 195: 331–336. doi: 10.1002/jcp.10301
- Issue published online: 14 APR 2003
- Article first published online: 31 MAR 2003
- Manuscript Accepted: 31 JAN 2003
- Manuscript Received: 27 JAN 2003
- NIH. Grant Numbers: AR42936, AR46557
- Wound Biotechnology Foundation
- 1999. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol 112(4): 463–469. , , et al.
- 1997. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem 272(3): 1429–1432. , , et al.
- 2002. Signal transduction by the TGF-beta superfamily. Science 296(5573): 1646–1647. , .
- 1998. Dermagraft in the treatment of diabetic foot ulcers. J Cutan Med Surg 3(Suppl 1): S1–29, 32. .
- 1982. The cause of venous ulceration. Lancet 2(8292): 243–245. , .
- 1996. Transforming growth factor-beta receptor binding and function are decreased in psoriatic dermal endothelium. J Invest Dermatol 106(2): 225–231. , , et al.
- 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1): 156–159. , .
- 1985. Fine structural analysis of the human pro-alpha 1 (I) collagen gene. Promoter structure, AluI repeats, and polymorphic transcripts. J Biol Chem 260(4): 2315–2320. , , et al.
- 2000. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 8(5): 347–352. .
- 2001. The chronic wound: Failure to heal. In: FalangaVincent, editor. Cutaneous wound healing. London: Martin Dunitz Publishers. pp 155–164. .
- 1993. The “trap” hypothesis of venous ulceration. Lancet 341(8851): 1006–1008. , .
- 1999. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: Efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 7(4): 208–213. , , et al.
- 1998. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human skin equivalent investigators group. Arch Dermatol 134(3): 293–300. , , et al.
- 1999. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 7(4): 201–207. , .
- 1994. Low oxygen tension decreases receptor binding of peptide growth factors in dermal fibroblast cultures. Exp Cell Res 213(1): 80–84. , , et al.
- 1996. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 19(4): 350–354. , , et al.
- 1997. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. J Dermatol Sci 16(1): 59–66. , , et al.
- 2002. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 45(7): 1011–1016. , , et al.
- 2002. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF, and PDGF-AB compared to controls. Eur J Cell Biol 81(3): 153–160. , , et al.
- 1999. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res 291(2–3): 93–99. , , et al.
- 1995. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268(5215): 1336–1338. , , et al.
- 1998. TGF-beta signal transduction. Annu Rev Biochem 67: 753–791. .
- 2001. Smad regulation in TGF-beta signal transduction. J Cell Sci 114(Pt 24): 4359–4369. , , et al.
- 2000. Prognostic indicators in venous ulcers. J Am Acad Dermatol 43(4): 627–630. , , et al.
- 2000. Sequential cytokine therapy for pressure ulcers: Clinical and mechanistic response. Ann Surg 231(4): 600–611. , , et al.
- 1998. The future of recombinant growth factors in wound healing. Am J Surg 176(2A Suppl): 80S–82S. , , et al.
- 2001. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 9(5): 347–352. , , et al.
- 1999. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies. Wound Repair Regen 7(5): 335–346. , , et al.
- 2000a. Initiating the inflammatory phase of incisional healing prior to tissue injury. J Surg Res 92(1): 11–17. , , et al.
- 2000b. Efficacy of growth factors in the accelerated closure of interstices in explanted meshed human skin grafts. J Burn Care Rehabil 21(1 Pt 1): 5–9. , , et al.
- 2001. Senescence and the healing rates of venous ulcers. J Vasc Surg 33(6): 1206–1211. , .
- 1997. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg 26(6): 994–999, Discussion 999–1001. , , et al.
- 1995. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic ulcer study group. J Vasc Surg 21(1): 71–78, Discussion 79–81. .
- 1995. Enhanced collagen synthesis and transcription by peak E, a contaminant of l-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic. J Clin Invest 96(5): 2120–2125. , , et al.
- 1999. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors. Wound Repair Regen 7(6): 442–452. , , et al.
- 1997. Pericapillary fibrin cuffs in venous disease. A reappraisal. Dermatol Surg 23(10): 955–959. , .
- 2002. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. Embo J 21(14): 3749–3759. , , et al.